Press release: APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401

Important development step for promising cell therapy

  • Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors
  • Innovative new manufacturing and treatment process enables outpatient treatment within one day from cell collection to reinfusion
  • Phase Ib clinical trial evaluates immunological effects as well as safety and tolerability of APN401 in patients with advanced-stage solid tumors
  • APN401 is an autologous cell therapy designed to inhibit the immune checkpoint Cbl-b using RNAi technology

Press release (EN) | Presseaussendung (DE)